Skip to content
OpenCapital
Get started

Sarepta Therapeutics, Inc. SRPT Cash Provided by (Used in) Financing Activity, Including Discontinued Operation

Cash Provided by (Used in) Financing Activity, Including Discontinued Operation at other companies

Insmed logo
InsmedINSM
$29.51M+1.8%
Pfizer logo
PfizerPFE
——
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
——

Other financials

Income statement

See full
Revenue$730.8M-1.9%
Operating income-$300.4M-961%
Net income$331.0M+174%
EPS (diluted)-$4.60-1,343%

Balance sheet

See full
Cash & equivalents$464.5M+92.8%
Total debt$198.5M-3.4%
Total equity$1.5B+31.7%
Total assets$3.2B-8.3%

Cash flow

See full
Operating cash flow-$202.7M+65.3%
CapEx$2.1M-95.2%
Free cash flow-$204.8M+67.3%

Valuation

See full
Market cap$1.76B-63.1%

Profitability

See full
Operating margin-50.8%-1.6pp
Net margin4.6%+2.4pp
FCF margin-28.7%-9.2pp

Returns & leverage

See full
Return on equity-23.6%-28.5pp
Debt / equity0.1×0.0×
Current ratio4.6×+0.6×

Where this comes from

Reported directly by Sarepta Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The official record: Sarepta Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sarepta Therapeutics, Inc.'s cash provided by (used in) financing activity, including discontinued operation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Sarepta Therapeutics, Inc.'s cash provided by (used in) financing activity, including discontinued operation?
Sarepta Therapeutics, Inc. (SRPT) reported cash provided by (used in) financing activity, including discontinued operation of $241K in Q1 2026.
How has Sarepta Therapeutics, Inc.'s cash provided by (used in) financing activity, including discontinued operation changed year-over-year?
Sarepta Therapeutics, Inc.'s cash provided by (used in) financing activity, including discontinued operation decreased by 98.1% year-over-year, from $12.47M to $241K.
What is the long-term trend for Sarepta Therapeutics, Inc.'s cash provided by (used in) financing activity, including discontinued operation?
Over 4 years (2021 to 2025), Sarepta Therapeutics, Inc.'s cash provided by (used in) financing activity, including discontinued operation has grown at a -26.0% compound annual growth rate (CAGR), from $561.57M to -$168.34M.
What does cash provided by (used in) financing activity, including discontinued operation mean?
This metric measures the net cash flow between the company and its capital providers, including proceeds from debt or equity issuance and payments for dividends or share repurchases. It highlights how the company finances its operations and returns value to shareholders.